SCYNEXIS Reports Positive Phase I Results for Oral SCY-247

SCYNEXIS has announced encouraging Phase I data for SCY-247, a second-generation triterpenoid antifungal targeting invasive fungal infections. The trial evaluated oral administration in healthy subjects across single ascending doses (50–900 mg) and multiple ascending doses (50–300 mg) over seven days, with 66 subjects receiving SCY-247 and 22 on placebo.

SCY-247 was well-tolerated, with no serious or severe treatment-emergent adverse events. Most adverse events were mild or moderate, including headaches (16.7% vs 4.5% placebo) and diarrhea (9% in both groups). Pharmacokinetics were generally dose-proportional, supporting further clinical development.

01-10-2025